PD-1 inhibition and (Non-)Hodgkin lymphoma: promising outcomes in an emerging field
PD-1 inhibition and (Non-)Hodgkin lymphoma: prom
Finding the way among a multitude of targets and regimens
Finding the way among a multitude of targets and
Advancing treatment in patients with mantle cell lymphoma
Advancing treatment in patients with mantle cell
Approaching marginal zone lymphoma from various angles
Approaching marginal zone lymphoma from various
Insights from early clinical trials on targeted treatment in B-cell malignancies
Insights from early clinical trials on targeted
Management of CLL patients: BTK inhibition and beyond
Management of CLL patients: BTK inhibition and b
What is new in Waldenström’s macroglobulinemia?
What is new in Waldenström’s macroglobulinemia?
多种实体瘤中的新型组合方法
多种实体瘤中的新型组合方法 乐伐替尼（lenvatinib）加派姆单抗 抗血管生成多激酶
卵巢癌：将PARP抑制更进一步
卵巢癌：将PARP抑制更进一步 尼拉帕利（niraparib）的个性化用量 根据NOVA
将创新从实验室带入临床实践
将创新从实验室带入临床实践 Andrés Cervantes, MD, PhD, 西班牙
